KYTHERA Biopharmaceuticals to Release Third Quarte

CALABASAS, Calif., Nov. 1, 2013 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH ) today announced it will release its third quarter 2013 operating results and will host an investor call and webcast at 1:30 p.m. PST on Thursday, November 14, 2013.

Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number 90439630. To access the webcast, please visit the Investors section of KYTHERA's website at www.kytherabiopharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting November 14, 2013, at approximately 4:30 p.m. PST, running through 11:59 p.m. PST on November 20, 2013. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 90439630. The archived webcast will be available on KYTHERA's website for seven days beginning approximately one hour after the call has completed.

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is currently in late stage clinical trials for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring.

Investor Contact: Heather Rowe Associate Director, Investor Relations Tel: (818) 587-4559